Microglia are the resident immune cells of the central nervous system (CNS) and play a critical role in maintaining brain homeostasis. In Alzheimer's disease (AD), microglia undergo profound phenotypic changes, transitioning from a surveillance state to a disease-associated phenotype that can both protect and harm the brain. Understanding microglia function in AD is crucial for developing therapeutic interventions that modulate neuroinflammation and enhance amyloid-beta clearance.
| Property | Value |
|---|---|
| Category | Immune Cells |
| Location | CNS, brain parenchyma, hippocampus, cortex |
| Cell Types | DAM (Disease-Associated Microglia), MGnD (Microglia with Neurodegenerative Phenotype), homeostatic microglia |
| Primary Neurotransmitter | Cytokines, chemokines, ROS, RNS |
| Key Markers | TREM2, CD33, APOE, CX3CR1, IBA1, CD68, C1q |
Under normal conditions, microglia maintain a surveillance phenotype characterized by highly ramified morphology with small cell bodies and long, thin processes. These cells continuously scan their environment for pathogens, cellular debris, and signs of neural dysfunction. Key markers include CX3CR1, P2RY12, and TMEM119.
In AD, microglia transition to a disease-associated (DAM) phenotype characterized by downregulated surveillance markers and upregulated disease-related genes. DAM progression occurs in two phases:
The microglia neurodegenerative (MGnD) phenotype emerges in response to chronic inflammation and is characterized by:
Triggering receptor expressed on myeloid cells 2 (TREM2) is a critical regulator of microglial function in AD. Rare TREM2 variants significantly increase AD risk, comparable to APOE4.
TREM2 deficiency in mouse models results in reduced microglial clustering around amyloid plaques, increased plaque burden, and impaired cognitive function. Conversely, TREM2 overexpression enhances microglial Aβ clearance and reduces pathology.
CD33 (sialic acid-binding Ig-like lectin 3) is a transmembrane receptor that modulates microglial activity:
Apolipoprotein E (APOE) plays a central role in microglial lipid metabolism and inflammatory responses:
The NLRP3 (NLR family pyrin domain containing 3) inflammasome is a key driver of neuroinflammation in AD:
Pro-inflammatory cytokines in AD include:
Microglia employ multiple strategies to clear amyloid-beta:
Microglia clear Aβ through autophagy:
Microglia produce proteases that degrade Aβ:
Microglia contribute to tau propagation and toxicity:
Pro-inflammatory cytokines promote tau pathology:
Microglia eliminate synapses through complement-mediated pruning:
| Gene | Variant | Effect on Microglia |
|---|---|---|
| TREM2 | R47H, R62H | Increased AD risk, impaired phagocytosis |
| CD33 | rs3865444 | Protective, reduced expression |
| APOE | ε4 | Impaired Aβ clearance, increased inflammation |
| PLCG2 | P522R | Protective, enhanced microglia function |
Mouse models of AD reveal microglia:
Current research focuses on:
The study of Microglia In Alzheimer'S Disease has evolved significantly over the past decades. Research in this area has revealed important insights into the underlying mechanisms of neurodegeneration and continues to drive therapeutic development.
Historical context and key discoveries in this field have shaped our current understanding and will continue to guide future research directions.
Hansen DV, Hanson JE, Sheng M. Microglia in Alzheimer's disease. Journal of Cell Biology. 2018;217(2):459-472. DOI:10.1083/jcb.201709069
Keren-Shaul H, Spinrad A, Weiner A, et al. A Unique Microglia Type Associated with Alzheimer's Disease. Cell. 2017;169(7):1276-1290.e17. DOI:10.1016/j.cell.2017.05.018
Ulrich JD, Holtzman DM. TREM2 Function in Alzheimer's Disease and Neurodegeneration. ACS Chemical Neuroscience. 2016;7(4):420-427. DOI:10.1021/acschemneuro.6b00026
Heneka MT, Kummer MP, Latz E. NLRP3 is activated in Alzheimer's disease and contributes to pathology in APP/PS1 mice. Nature. 2013;493(7434):674-678. DOI:10.1038/nature11729
Shi Y, Holtzman DM. Interplay between innate immunity and Alzheimer disease: APOE and TREM2 in the spotlight. Nature Reviews Immunology. 2018;18(12):759-772. DOI:10.1038/s41577-018-0051-1
Wang J, Gu BJ, Masters CL, Wang YJ. A systemic view of Alzheimer disease - from insights to therapeutic opportunities. Signal Transduction and Targeted Therapy. 2021;6(1):392. DOI:10.1038/s41392-021-00789-9
Zhou Y, Ulland TK, Colonna M. TREM2-Dependent Effects on Microglia in Alzheimer's Disease. Frontiers in Aging Neuroscience. 2018;10:202. DOI:10.3389/fnagi.2018.00202
Deczkowska A, Amit I, Schwartz M. Microglial immune checkpoint functions. Nature Neuroscience. 2015;18(7):952-961. DOI:10.1038/nn.4048
Salter MW, Stevens B. Microglia emerge as central players in brain disease. Nature Medicine. 2017;23(9):1018-1027. DOI:10.1038/nm.4397
Lewcock JW, Schlepckow K, Di Paolo G, et al. Microglial Death. Neuron. 2020;108(4):619-636. DOI:10.1016/j.neuron.2020.10.027